Quick Answer
Cocrystal Pharma, Inc. reported R&D Expense of $5.05 million for fiscal year 2025.
Cocrystal Pharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $5.05M | -59.7% |
| 2024 | $12.54M | -17.4% |
| 2023 | $15.17M | +22.4% |
| 2022 | $12.39M | +40.9% |
| 2021 | $8.79M | +45.7% |
| 2020 | $6.03M | +50.7% |
| 2019 | $4.00M | -14.2% |
| 2018 | $4.67M | -19.8% |
| 2017 | $5.82M | -94.3% |
| 2016 | $101.68M | +115.1% |
| 2015 | $47.26M | +1060.9% |
| 2014 | $4.07M | +5.4% |
| 2013 | $3.86M | +689.2% |
| 2012 | $489.3K | +15.6% |
| 2011 | $423.2K | +75.7% |
| 2010 | $240.9K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $954.0K | -70.6% | -15.0% |
| June 30, 2025 | $1.12M | -74.0% | -17.5% |
| March 31, 2025 | $1.36M | -53.9% | -58.1% |
| September 30, 2024 | $3.24M | -22.7% | -24.7% |
| June 30, 2024 | $4.31M | +53.8% | +46.0% |
| March 31, 2024 | $2.95M | -24.5% | -29.7% |
| September 30, 2023 | $4.19M | +8.3% | +49.7% |
| June 30, 2023 | $2.80M | +18.6% | -28.3% |
- Cocrystal Pharma, Inc. showed a decrease of -59.7% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, Cocrystal Pharma, Inc.’s r&d expense has grown by 1998.6% (from $240.9 thousand to $5.05 million).
- The most recent figure is from Cocrystal Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: